SCHEMBL20873246

SCHEMBL20873246

Oc1ccc(N2CCN(C[C@H]3O[C@H](O)[C@H](O)[C@@H](O)[C@H]3O)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 4/20 0.44
▸ DRD3 P35462 2/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ GAA P10253 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ MAPT P10636 4/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HTR7 P34969 3/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ PKM P14618 1/20 0.39
▸ ME2 P23368 1/20 0.39
▸ ME1 P48163 1/20 0.39
▸ ME3 Q16798 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ TYR P14679 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ DRD1 P21728 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873286 0.88 DRD4 (0.45) DRD4DRD3DRD2GAAKDM4E
SCHEMBL20873314 0.81 MAPT (0.48) DRD4GAAKDM4EMAPTLMNA
SCHEMBL24138061 0.81 MAPT (0.48) DRD4GAAKDM4EMAPTLMNA
SCHEMBL20873281 0.75 SLC5A2 (0.43) DRD4DRD3DRD2GAAKDM4E
SCHEMBL21148624 0.75 SLC5A2 (0.43) DRD4DRD3DRD2GAAKDM4E
SCHEMBL21148625 0.75 SLC5A2 (0.43) DRD4DRD3DRD2GAAKDM4E
Beta-D-Glucose SCHEMBL162950 0.71 TYR (0.62) GAAKDM4EMAPTTYRPOLB
SCHEMBL7041242 0.69 MAPT (0.68) DRD4DRD3DRD2GAAKDM4E
SCHEMBL21148637 0.69 ALDH1A1 (0.41) DRD4DRD3DRD2GAAKDM4E
SCHEMBL24137899 0.69 ALDH1A1 (0.41) DRD4DRD3DRD2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
EP-3463480-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2019-04-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 DRD4 4226/4885DRD3 4609/4885DRD2 4570/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 DRD4 4226/4885DRD3 4609/4885DRD2 4570/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 DRD4 4226/4885DRD3 4609/4885DRD2 4570/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 DRD4 4226/4885DRD3 4609/4885DRD2 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback